Compare FVRR & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FVRR | NERV |
|---|---|---|
| Founded | 2010 | 2007 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 372.4M | 301.6M |
| IPO Year | 2019 | 2014 |
| Metric | FVRR | NERV |
|---|---|---|
| Price | $11.53 | $6.26 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 2 |
| Target Price | ★ $18.43 | $10.50 |
| AVG Volume (30 Days) | ★ 879.5K | 180.1K |
| Earning Date | 04-29-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,175,600.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.83 | N/A |
| P/E Ratio | $22.05 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.67 | $1.30 |
| 52 Week High | $34.13 | $12.46 |
| Indicator | FVRR | NERV |
|---|---|---|
| Relative Strength Index (RSI) | 56.40 | 48.40 |
| Support Level | $9.97 | $5.83 |
| Resistance Level | $17.34 | $6.69 |
| Average True Range (ATR) | 0.59 | 0.51 |
| MACD | 0.17 | -0.03 |
| Stochastic Oscillator | 47.91 | 22.94 |
Fiverr International Ltd operates a online marketplace that enables sellers to offer digital services and buyers to purchase them The Company's platform features an extensive catalog of digital services that spans over hundreds of categories. Buyers can purchase digital services ranging from simple services such as logo design and blog post writing, to complex services such as video creation, website development and social media marketing. Also, the Company offers value-added services including subscription products, advertising solutions and financial tools designed to support marketplace users and enhance their business activities. The company generates maximum of its revenue from USA.
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.